Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Xue Bai^{1

2}, Ahmed Shaheen³, Charlotte Grieco⁴, Paolo D d'Arienzo⁴, Florentia Mina⁴, Juliane A Czapla², Aleigha R Lawless², Eleonora Bongiovanni⁵, Umberto Santaniello⁵, Helena Zappi⁶, Dominika Dulak⁷, Andrew Williamson⁸, Rebecca Lee⁹, Avinash Gupta⁸, Caili Li¹, Lu Si¹, Martina Ubaldi¹⁰, Naoya Yamazaki¹¹, Dai Ogata¹¹, Rebecca Johnson¹², Benjamin C Park¹³, Seungyeon Jung¹³, Gabriele Madonna¹⁴, Juliane Hochherz¹⁵, Yoshiyasu Umeda¹⁶, Yasuhiro Nakamura¹⁶, Christoffer Gebhardt¹⁵, Lucia Festino¹⁴, Mariaelena Capone¹⁴, Paolo Antonio Ascierto¹⁴, Douglas B Johnson¹³, Serigne N Lo^{17

18}, Georgina V Long¹², Alexander M Menzies¹², Kenjiro Namikawa¹¹, Mario Mandala¹⁰, Jun Guo¹, Paul Lorigan⁹, Yana G Najjar¹⁹, Andrew Haydon⁶, Pietro Quaglino⁵, Genevieve M Boland², Ryan J Sullivan², Andrew J S Furness⁴, Ruth Plummer³, Keith T Flaherty²

Affiliations

¹ Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, China.
² Massachusetts General Hospital, USA.
³ Newcastle University Centre for Cancer, UK.
⁴ Skin Unit, The Royal Marsden NHS Foundation Trust, London, UK.
⁵ Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Italy.
⁶ Alfred Health, Australia.
⁷ Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
⁸ The Christie NHS Foundation Trust, Manchester, UK.
⁹ Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK.
¹⁰ University of Perugia, Italy.
¹¹ Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
¹² Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
¹³ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁴ Department of Melanoma, Cancer Immunotherapy and Development Therapeutics - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
¹⁵ Department of Dermatology, University Medical Center Hamburg-Eppendorf (UKE), University Skin Cancer Center, Hamburg, Germany.
¹⁶ Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
¹⁷ Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney, North Sydney, NSW, Australia.
¹⁸ Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
¹⁹ UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

PMID: 38572079
PMCID: PMC10990704
DOI: 10.1016/j.eclinm.2024.102564

Published Erratum

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Xue Bai et al. EClinicalMedicine. 2024.

. 2024 Mar 27:71:102564.

doi: 10.1016/j.eclinm.2024.102564. eCollection 2024 May.

Authors

Affiliations

¹ Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, China.
² Massachusetts General Hospital, USA.
³ Newcastle University Centre for Cancer, UK.
⁴ Skin Unit, The Royal Marsden NHS Foundation Trust, London, UK.
⁵ Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Italy.
⁶ Alfred Health, Australia.
⁷ Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
⁸ The Christie NHS Foundation Trust, Manchester, UK.
⁹ Division of Cancer Sciences, University of Manchester and Christie NHS Foundation Trust, Manchester, UK.
¹⁰ University of Perugia, Italy.
¹¹ Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
¹² Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, Australia.
¹³ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
¹⁴ Department of Melanoma, Cancer Immunotherapy and Development Therapeutics - Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
¹⁵ Department of Dermatology, University Medical Center Hamburg-Eppendorf (UKE), University Skin Cancer Center, Hamburg, Germany.
¹⁶ Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan.
¹⁷ Melanoma Institute Australia, The University of Sydney; Faculty of Medicine and Health, The University of Sydney, North Sydney, NSW, Australia.
¹⁸ Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
¹⁹ UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

PMID: 38572079
PMCID: PMC10990704
DOI: 10.1016/j.eclinm.2024.102564

No abstract available

PubMed Disclaimer

Erratum for

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Bai X, et al. EClinicalMedicine. 2023 Oct 31;65:102290. doi: 10.1016/j.eclinm.2023.102290. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37965433 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Affiliations

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources